Scott Kathleen D. — SEC Form 4 filings
SEC reporting owner CIK 1794284. 11 Form 4 filings on record with FilingPulse; latest filed 2026-06-16.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-02-14 to 2026-06-16. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 5 legs across 5 filings — 87,511 shares, $1,292,678 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 15.
- Largest priced transaction: sale of 50,000 shares @ $14.10 ($705,165) in ARS Pharmaceuticals, Inc., filed 2025-05-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | Chief Financial Officer | 6 | — | 4 legs · 87,500 sh · $1,292,665 | 10 |
| Dermata Therapeutics, Inc. (DRMA) | Director | 3 | — | 1 leg · 11 sh · $13 | 2 |
| NKGen Biotech, Inc. (NKGN) | Director | 2 | — | — | 3 |
Form 4 filings — Scott Kathleen D.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-16 | 4 | Dermata Therapeutics, Inc. (DRMA) | Sale (S): 11 @ $1.19 | EDGAR |
| 2026-01-06 | 4 | Dermata Therapeutics, Inc. (DRMA) | Grant/award (A): 2,500 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2025-08-22 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Option exercise (M): 12,500 @ $1.50 · Sale (S): 12,500 @ $15 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Option exercise (M): 50,000 @ $1.50 · Sale (S): 50,000 @ $14.10 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2025-01-14 | 4 | Dermata Therapeutics, Inc. (DRMA) | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Grant/award (A): 176,700 (derivative) @ $0 | EDGAR |
| 2024-12-10 | 4 | NKGen Biotech, Inc. (NKGN) | Grant/award (A): 300,000 (derivative) @ $0 · Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2024-10-17 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Option exercise (M): 12,500 @ $1.50 · Sale (S): 12,500 @ $16 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2024-08-21 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Option exercise (M): 12,500 @ $1.50 · Sale (S): 12,500 @ $16 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | NKGen Biotech, Inc. (NKGN) | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1794284 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →